| Nov 15 |
Cyclacel Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations
|
| Nov 14 |
Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds
|
| Nov 14 |
Why DLocal Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
|
| Nov 13 |
Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds
|
| Nov 13 |
Why Rocket Lab Shares Are Trading Higher By Around 29%; Here Are 20 Stocks Moving Premarket
|
| Nov 12 |
Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q3 Loss
|
| Nov 12 |
Cyclacel Pharmaceuticals GAAP EPS of -$0.18 beats by $0.36, revenue of $0.01M in-line
|
| Nov 12 |
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
|
| Oct 24 |
Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule
|
| Oct 23 |
Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
|
